Billiontoone (NASDAQ:BLLN) SVP Bosch John Roderick Ten Sells 1,417 Shares

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,417 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62. Following the completion of the transaction, the senior vice president directly owned 27,884 shares in the company, valued at $2,589,308.24. This represents a 4.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total value of $169,920.00.
• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The shares were sold at an average price of $101.47, for a total value of $287,363.04.

Billiontoone Stock Down 0.5%

Shares of Billiontoone stock opened at $97.45 on Thursday. The stock has a market capitalization of $4.48 billion and a price-to-earnings ratio of 139.21. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The business’s 50 day simple moving average is $116.70 and its 200-day simple moving average is $94.55.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The firm had revenue of $109.45 million during the quarter. Equities research analysts forecast that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds have recently made changes to their positions in the business. Adams Street Partners LLC acquired a new stake in Billiontoone during the fourth quarter valued at approximately $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone in the fourth quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone in the fourth quarter worth approximately $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone in the fourth quarter valued at $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone in the first quarter valued at $29,179,000.

Wall Street Analysts Forecast Growth

BLLN has been the topic of a number of analyst reports. BTIG Research dropped their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Guggenheim started coverage on shares of Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 target price for the company. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. cut their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Finally, Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $126.71.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.